Vor Biopharma opened lower at $19.61, compared with its previous close of $20.09. In the last trading session, the stock traded between $18.99 and $19.88. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Vor Biopharma is now worth
$ 5.77
Resulting in a loss of
$ 94.23 (94.23%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.77 (-3.81%)
Day High
$19.88
Day Low
$18.99
Day Open
$19.61
Prev Close
$20.09
Volume
5,69,037
1W Return
-3.78%
1M Return
-2.27%
3M Return
-18.01%
6M Return
12.03%
1Y Return
96.39%
Fundamentals
Market Cap ($ Mn)
1,187
PE Ratio
0.13
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-365.62%
EPS (TTM)
$-1.41
Investment Returns
1 Week
-3.78%
1 Month
-2.27%
3 Months
-18.01%
6 Months
12.03%
9 Months
44.87%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
21Oct
William Blair initiates Vor Biopharma with Outperform rating
William Blair initiated coverage on Vor Biopharma. Analyst Myles Minter assigned an Outperform rating. Coverage initiation indicates a positive sector outlook.
22 days ago
6Oct
Vor Bio grants inducement stock options to nine new hires
Granted 59,250 stock options and 12,550 RSUs to nine new employees. Stock options have an exercise price of $18.06 per share. Grants made under Nasdaq Listing Rule 5635(c)(4) as employment inducements. Awards vest over four years with a one-year cliff.
1mo ago
29Sep
Vor Bio partner RemeGen reports 95% MG-ADL response in Phase 3 trial
Vor Bio announced post hoc data from RemeGen's Phase 3 trial. Over 95% of gMG patients achieved at least 5-point MG-ADL improvement. Data presented at AANEM Annual Meeting in Orlando. Trial conducted in China over 48 weeks.
1mo ago
5Sep
Vor Bio grants stock options and RSUs to six new hires
Vor Bio granted 83,600 stock options and 17,900 RSUs to six new hires. Awards were made under Nasdaq Listing Rule 5635(c)(4) as material inducements. Stock options have an exercise price of $22.64 per share and a ten-year term. All equity awards vest over four years with a 25% cliff after one year.
2mo ago
12Aug
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate
Vor Biopharma's Q2 adjusted EPS of $(0.80) missed analyst estimates but showed a 98.17% improvement in losses compared to the prior year. The company maintains strong liquidity funding operations into early 2029.
3mo ago
4Aug
Vor Bio grants $21.15 strike options and RSUs to five new hires
Vor Bio granted 32,550 stock options and 6,900 RSUs to five new employees on August 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of $21.15 per share. Both awards vest over four years, with a 25% cliff after 12 months.
